Edgewise Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and has a $42.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including Edgewise Therapeutics’ strong financial position and promising clinical developments. The company reported a better-than-expected EPS for 2Q25 and ended the quarter with $594 million in cash, indicating robust financial health.
Moreover, Edgewise is making significant progress in its clinical programs, particularly in the development of treatments for skeletal muscle and cardiac conditions. The company has shown positive results in multiple trials, including the MESA OLE trial for BMD and the Phase 2 CIRRUS-HCM trial for HCM. With plans to advance into pivotal studies and ongoing discussions with the FDA, Edgewise is well-positioned for future growth and success in its therapeutic areas.
In another report released on July 29, Raymond James also initiated coverage with a Buy rating on the stock with a $46.00 price target.